Artikler

Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.¹

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

Think Fabry, think timely testing first.

Think Fabry, think regular profile-based assessments.

Cardiovascular disease is the leading cause of death in Fabry disease patients.¹ Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.^2,3

Think Fabry, think renal involvement that may present early in life and could go undetected.

Think Fabry, think screening at-risk family members.¹

Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.^1,2

Beneath the skin of patients with AD—type 2 inflammation and the cytokines involved.

Unpredictable blood glucose readings, extreme fatigue, and an overwhelming fear of low blood glucose—this is how Ingunn describes the early days after her son, Olav, was diagnosed with type 1 diabetes. It has been a time of sleepless nights and many worries. But it has also been a time of learning, adaptation, and strengthened family bonds.

Silje Elfrida (36) lives in Tjodalyng, near Larvik, works in the healthcare sector, and leads a busy life with two very active sons aged seven and five. At the same time, she is navigating an uncertain romantic situation. Diagnosed with type 1 diabetes at the age of 19 in 2007, Silje Elfrida took on the challenge immediately, determined not to let the condition limit her life.